3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
10
Head & Neck
3
Gastrointestinal
3
Tumor-Agnostic
2
Gynecologic
2
Other hematologic neoplasm
1
Other
1
Genitourinary
1
Dermatologic
1
Conditions
Smoking Cessation
1
Melanoma
1
Gastrointestinal Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
326
Nivolumab
289
Ipilimumab
260
Cyclophosphamide
193
aldesleukin
145
Interleukin-2
109
fludarabine phosphate
106
Temozolomide
83
Dacarbazine
81
fludarabine
80
Radiotherapy
74
trametinib
73
Vemurafenib
69
dabrafenib
66
Biopsy
65
sargramostim
50
Bevacizumab
50
Radiosurgery
49
Paclitaxel
49
Peripheral Blood Stem Cell Transplantation
48
Carboplatin
48
Magnetic Resonance Spectroscopy
47
Imiquimod
47
Aminolevulinic Acid
47
binimetinib
45
Cisplatin
45
CTLA-4 Antigen
43
cemiplimab
42
atezolizumab
41
Specimen Handling
40
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Hypnosis
×
Dermatologic
×
Clear all
NCT04899492
2024-11-07
RESPIRE
Institut Cancerologie de l'Ouest
Phase NA
Terminated
22 enrolled